Does Christiana Care Health System Cover Cialis?

What Is ChristianaCare and How Does It Relate to Insurance Coverage?

ChristianaCare is one of the largest not-for-profit health systems in the mid-Atlantic region, operating hospitals, outpatient centers, and an employed physician network primarily in Delaware, Maryland, and southeastern Pennsylvania. The health system itself does not issue insurance policies. Coverage decisions for Cialis belong to the insurer attached to a patient's plan, whether that is a commercial carrier, a Medicare Part D plan, or Delaware Medicaid.

That distinction matters practically. A patient seen by a ChristianaCare urologist will have their prescription processed through whichever pharmacy benefit the patient's own plan administers. ChristianaCare's formulary committee governs medications stocked in its own hospital pharmacies; outpatient prescriptions follow the patient's external plan rules entirely.

Why the Health System's Name Appears in Coverage Questions

Patients often conflate the name of the hospital or physician group with the insurer. ChristianaCare does offer employee health benefits through commercial carriers such as Highmark Blue Cross Blue Shield of Delaware, and those plans have their own formularies. If a patient is asking whether Highmark coverage obtained through ChristianaCare employment covers Cialis, the answer lies in Highmark's drug formulary, not in ChristianaCare's clinical policies.

Employer-Sponsored Plans at ChristianaCare

ChristianaCare's published benefits materials indicate that prescription coverage for employees follows the standard Highmark Blue Cross Blue Shield of Delaware tiered formulary. Generic tadalafil typically lands on Tier 2 (preferred generic), while brand Cialis lands on Tier 3 or Tier 4 (non-preferred brand). Tier 3 copays commonly run $45 to $75 per fill under employer-sponsored plans, though the exact figure requires verification with the specific plan year's Summary of Benefits and Coverage document.

How FDA Approval Status Affects Tadalafil Coverage

Tadalafil holds three distinct FDA-approved indications, and insurers treat each one differently. The FDA approved tadalafil for erectile dysfunction in 2003, for pulmonary arterial hypertension (as Adcirca) in 2009, and for benign prostatic hyperplasia (BPH) as a 5 mg daily dose in 2011.

Erectile Dysfunction Indication

Coverage for the ED indication is the most restricted. Federal law under 42 U.S.C. § 1395w-102(e) explicitly prohibits Medicare Part D plans from covering drugs used solely to treat sexual dysfunction. Commercial insurers are not bound by the same statute, but many mirror the restriction voluntarily to limit costs.

BPH Indication

The BPH indication changes the calculus. Tadalafil 5 mg daily for BPH is medically necessary treatment for a chronic, non-sexual condition. The AUA guideline on benign prostatic hyperplasia endorses PDE5 inhibitors as first-line therapy when lower urinary tract symptoms coexist with ED. Many insurers, including Delaware Medicaid managed-care plans, cover tadalafil for BPH when the diagnosis code (N40.1 or N40.0) is included on the prior authorization form.

Pulmonary Arterial Hypertension Indication

Tadalafil for pulmonary arterial hypertension (PAH) is classified as a specialty drug and generally carries its own coverage pathway through specialty pharmacy. This indication is outside the scope of most ED-related coverage questions, but it confirms that the molecule itself is not categorically uninsurable.

Medicare Part D and Cialis: The Federal Exclusion Explained

Medicare Part D by statute cannot cover drugs whose primary purpose is to treat sexual or erectile dysfunction. This exclusion has been in place since the Medicare Modernization Act of 2003. ChristianaCare's Medicare Advantage and Part D plan partners, including plans administered through Highmark and other carriers, must comply with this federal prohibition.

Exceptions Within Medicare

A narrow exception exists when tadalafil is prescribed for a covered indication alongside ED. If a patient has a documented BPH diagnosis and the prescription is written for 5 mg daily for lower urinary tract symptoms, some Medicare Advantage plans will cover it after prior authorization. The CMS formulary exception process allows physicians to request coverage when a non-covered drug is the only medically appropriate option, though this route is infrequently successful for ED-only claims.

Medicare Advantage Plans in Delaware

Delaware Medicare Advantage beneficiaries treated at ChristianaCare facilities are commonly enrolled in Highmark Blue Cross Blue Shield of Delaware Medicare Advantage or Aetna Medicare Advantage plans. Both plans' publicly posted formularies list tadalafil for ED as excluded per federal law. Tadalafil for BPH appears on Highmark's Delaware Medicare Advantage formulary at Tier 2 with a quantity limit of 30 tablets per 30 days at the 5 mg strength.

Commercial Insurance Coverage for Tadalafil

For patients under age 65 with employer-sponsored or ACA marketplace coverage, Cialis coverage is more variable but often achievable with the right documentation.

Prior Authorization Requirements

The majority of commercial plans that cover tadalafil require prior authorization (PA). A PA form typically asks the prescribing physician to confirm:

• The patient has a confirmed diagnosis of ED, BPH, or both
• The patient has tried at least one other PDE5 inhibitor (step therapy is common; sildenafil is often required first because generic sildenafil costs less)
• No contraindications exist, such as concurrent nitrate use

The ACC/AHA cardiovascular guidance on PDE5 inhibitors notes that PDE5 inhibitors are contraindicated with nitrates due to risk of severe hypotension. Payers use this as a safety screen as well as a cost-containment tool.

Step Therapy: Sildenafil First

Most commercial formularies require a trial of generic sildenafil before approving brand Cialis or even generic tadalafil at higher tiers. Sildenafil 50 mg costs roughly $10 to $20 for a 30-day supply at GoodRx pricing. If a patient fails sildenafil due to side effects (flushing, visual disturbance, or the need for on-demand versus daily dosing), the prescriber can document that and request a step therapy exception for tadalafil daily dosing.

ACA Marketplace Plans in Delaware

Delaware's ACA marketplace offers plans through Highmark Blue Cross Blue Shield of Delaware and Ambetter. Neither plan is required by the ACA's essential health benefits mandate to cover ED medications, as the HHS essential health benefits framework does not include sexual dysfunction drugs. Coverage depends entirely on the plan's voluntary formulary design.

Delaware Medicaid and Tadalafil

Delaware Medicaid is administered through managed-care organizations (MCOs) including Highmark Health Options and AmeriHealth Caritas Delaware. The Delaware Division of Medicaid and Medical Assistance (DMMA) publishes preferred drug lists that govern coverage.

What Delaware Medicaid Covers

Delaware Medicaid's preferred drug list generally excludes PDE5 inhibitors for the ED indication alone. A 2023 analysis published in JAMA Network Open found that only 27 of 50 state Medicaid programs covered any PDE5 inhibitor for ED, and the majority imposed strict quantity limits. Delaware falls in the more restrictive category.

For BPH, coverage follows the managed-care plan's formulary. Patients should ask their MCO directly whether tadalafil 5 mg daily for BPH (diagnosis code N40.1) is a covered benefit before the prescription is filled.

PA Process for Medicaid Members

Medicaid prior authorization for tadalafil (when covered for BPH) typically requires the prescribing provider to submit a PA request through the MCO's portal. Documentation should include the ICD-10 code, symptom severity (often quantified via the International Prostate Symptom Score), and any prior alpha-blocker trials. The AUA BPH guideline recommends PDE5 inhibitors when LUTS and ED coexist, and citing this guideline in the PA narrative has been associated with higher approval rates in clinical practice.

The Evidence Base for Tadalafil: Why Payers Scrutinize This Drug

Understanding why payers restrict Cialis requires reviewing the clinical data that drove its approval and its cost profile.

ED Efficacy Data

The key tadalafil ED trials submitted to the FDA demonstrated that tadalafil 20 mg produced successful intercourse in 75% of attempts versus 32% for placebo (P<0.001) in the registration studies. A Cochrane systematic review of PDE5 inhibitors covering 82 trials and 17,696 men confirmed that all approved PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) produce clinically meaningful improvements in IIEF scores, with no clear superiority of one agent over another on efficacy. Because generic sildenafil costs far less and has equivalent average efficacy, payers default to it as the preferred first-line agent.

BPH Efficacy Data

A placebo-controlled trial published in the Journal of Urology (N=325) showed tadalafil 5 mg daily significantly improved International Prostate Symptom Score by 3.2 points versus 1.6 for placebo (P<0.001) over 12 weeks. This strong separation from placebo justified the FDA approval and gives insurers less grounds to deny coverage when BPH is the documented indication.

Cardiovascular Safety

The CONFIRM trial program and post-market surveillance data show tadalafil is generally well tolerated in men without active nitrate use, with headache (14%), dyspepsia (10%), and back pain (6%) as the most common adverse events. The ACC/AHA position statement states that PDE5 inhibitors are safe in stable cardiovascular disease patients not taking nitrates. Payers require the nitrate contraindication screen in PA forms because a drug-drug interaction causing severe hypotension would be a liability.

How to Get Tadalafil Covered at ChristianaCare-Affiliated Practices

A step-by-step approach gives patients the best chance of approval.

Step 1: Verify Your Exact Plan Formulary

Call the member services number on the back of your insurance card and ask specifically: "Is tadalafil on my formulary, and at what tier? Is prior authorization required?" Do not rely on the health system's website for this. The insurer's current year formulary document is the binding source.

Step 2: Ask Your Provider About the BPH Indication

If lower urinary tract symptoms are present alongside ED, ask the ChristianaCare urologist or primary care physician whether a BPH diagnosis can be documented. A formal assessment using the International Prostate Symptom Score (IPSS) takes under three minutes in the clinic and creates the clinical basis for prescribing tadalafil 5 mg daily for a covered indication.

Step 3: Complete Sildenafil Step Therapy First

Try generic sildenafil for at least 30 days if your plan requires it. If it does not work because of side effects or because daily dosing is preferred over on-demand dosing, document that in the medical record. Tadalafil's half-life of approximately 17.5 hours enables daily dosing that sildenafil cannot replicate. FDA labeling for tadalafil specifically lists the daily 5 mg and 2.5 mg doses as distinct from the on-demand 10 mg and 20 mg doses.

Step 4: Submit a Prior Authorization With Strong Clinical Documentation

The PA should include the ICD-10 diagnosis code (F52.21 for male ED, N40.1 for BPH with LUTS), IIEF-5 or IPSS score, contraindications checked (confirm no nitrate use), any step therapy already completed, and a brief clinical narrative citing the relevant guideline.

Step 5: Appeal a Denial

If the PA is denied, the prescriber can file a peer-to-peer review request, typically within 30 calendar days of the denial letter. Citing the AUA guideline recommendation for PDE5 inhibitors in BPH and the published IIEF score data strengthens the appeal. A 2019 study in Health Affairs found that physician-initiated peer-to-peer reviews overturn initial PA denials at rates between 32% and 75% depending on the payer category.

Cost-Reduction Strategies When Insurance Does Not Cover Cialis

When coverage is denied or unavailable, patients have several concrete options to reduce out-of-pocket costs.

Generic Tadalafil

Brand Cialis lost its U.S. Patent exclusivity in 2018. Generic tadalafil 5 mg (30 tablets) costs approximately $15 to $25 at major pharmacy chains using discount programs such as GoodRx or the pharmacy's own generic pricing. The tadalafil 20 mg tablet (on-demand dosing) runs roughly $20 to $45 for a 6-count supply. These prices are dramatically below the $400 to $500 monthly cost of brand Cialis without insurance.

Manufacturer Programs

Eli Lilly, the maker of Cialis, no longer offers a significant patient assistance program for tadalafil now that generics are available. Generic manufacturers do not typically run branded coupons. However, the NeedyMeds database and RxAssist list state pharmaceutical assistance programs that may help low-income patients in Delaware.

Telehealth Prescribing for ED

Several digital health platforms now offer generic tadalafil prescriptions at cash-pay prices between $15 and $30 per month after an online consultation. This approach bypasses insurance entirely and may be faster than the PA process. Patients should confirm the telehealth platform's Delaware licensure before using it.

90-Day Supply

Requesting a 90-day supply at a mail-order pharmacy typically reduces the per-tablet cost by 15% to 20% under plans that cover tadalafil. Mail-order fills also reduce dispensing fees compared to 30-day retail fills.

What Clinicians at ChristianaCare Facilities Should Know

Physicians, advanced practice providers, and clinical pharmacists at ChristianaCare-affiliated practices can take specific actions to improve patients' coverage outcomes.

Document IPSS and IIEF Scores Routinely

Standardized scoring at baseline creates the clinical record needed for PA submissions. The IPSS is a validated 7-item questionnaire; an IPSS of 8 or higher supports the BPH indication. A 2020 review in the New England Journal of Medicine described BPH and ED as frequently coexisting conditions with shared pathophysiology involving smooth muscle tone and nitric oxide signaling, reinforcing that dual documentation is clinically appropriate and not a billing workaround.

Use the Correct ICD-10 Codes on the Prescription

A prescription written only with F52.21 (ED) will almost certainly be denied under Medicare and many commercial plans. Adding N40.1 (BPH with LUTS) when that diagnosis is supported by the clinical record can change the coverage determination.

Proactive Patient Counseling on Generic Availability

Prescribers should inform patients at the point of prescribing that generic tadalafil has been available since 2018 and that cash-pay prices make it accessible even without insurance. A JAMA Internal Medicine commentary noted that generic entry for PDE5 inhibitors significantly reduced patient cost burden and should be communicated during shared decision-making.

Coordinate With the ChristianaCare Pharmacy Team

ChristianaCare's integrated pharmacy services team can assist with PA submissions for patients in the employed physician network. Outpatient pharmacists affiliated with ChristianaCare offices are often able to initiate PA requests and track appeal timelines, reducing the burden on the prescribing physician's office staff.

Summary of Coverage by Insurance Type

| Insurance Type | Tadalafil for ED | Tadalafil for BPH | Notes | |---|---|---|---| | Medicare Part D | Excluded by federal law | Covered on most plans (Tier 2, PA required) | Peer-to-peer appeal rarely succeeds for ED | | Delaware Medicaid | Generally excluded | May be covered (MCO-specific, PA required) | Verify with Highmark Health Options or AmeriHealth Caritas | | Employer plan (Highmark via ChristianaCare) | Tier 2 to Tier 3, PA required | Tier 2, PA required | Step therapy to sildenafil common | | ACA Marketplace (Delaware) | Plan-dependent, not mandated | Plan-dependent | Confirm with current year formulary | | No insurance / cash pay | Generic tadalafil $15 to $25/month | Same | Generic available since 2018 |